Regulation of editing and expression of glutamate α-amino-propionic- acid (AMPA)/kainate receptors by antidepressant drugs

Alessandro Barbon, Maurizio Popoli, Luca La Via, Stefania Moraschi, Ivan Vallini, Daniela Tardito, Ettore Tiraboschi, Laura Musazzi, Roberto Giambelli, Massimo Gennarelli, Giorgio Racagni, Sergio Barlati

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Background: Several reports have shown that the glutamatergic system is involved in both the pathogenesis of affective and stress-related disorders and in the action of antidepressant drugs. In particular, antidepressant treatment was shown to modulate expression and function of ionotropic glutamate receptors, to inhibit glutamate release and to restore synaptic plasticity impaired by stress. Methods: We analyzed the mRNA expression and RNA editing of α-amino-propionic-acid (AMPA) and kainate (KA) receptor subunits, in the pre-frontal/frontal cortex (P/FC) and hippocampus (HI) of rats chronically treated with three different drugs: the selective serotonin (5-HT) reuptake inhibitor fluoxetine, the selective noradrenaline (NA) reuptake inhibitor reboxetine and the tricyclic antidepressant desipramine. Results: Our data showed that fluoxetine and desipramine exerted moderate but selective effects on glutamate receptor expression and editing, while reboxetine appeared to be the drug that affects glutamate receptors (GluR) most. The most consistent effect, observed with pronoradrenergic drugs (desipramine and reboxetine), was a decrease of GluR3 expression both in P/FC and HI. Interestingly, in HI, the same drugs also decreased the editing levels of either the flip (desipramine) or flop (reboxetine) form of GluR3. Conclusions: Overall, these results point to specific and regionally discrete changes in the expression and editing level of glutamate receptors and, in particular, to a selective reduction of conductance for GluR3-containing receptors following treatment with antidepressant drugs. These data support the hypothesis that changes in glutamate neurotransmission are involved in the therapeutic effects induced by these drugs.

Original languageEnglish
Pages (from-to)713-720
Number of pages8
JournalBiological Psychiatry
Volume59
Issue number8
DOIs
Publication statusPublished - Apr 15 2006

Fingerprint

Kainic Acid Receptors
Desipramine
Antidepressive Agents
Glutamic Acid
Glutamate Receptors
Hippocampus
Fluoxetine
Frontal Lobe
Pharmaceutical Preparations
Amino Acid Receptors
RNA Editing
Serotonin Agents
Ionotropic Glutamate Receptors
Neuronal Plasticity
Tricyclic Antidepressive Agents
Therapeutic Uses
Synaptic Transmission
Serotonin
Norepinephrine
Messenger RNA

Keywords

  • Antidepressant
  • Expression
  • Glutamate receptors
  • RNA editing

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Regulation of editing and expression of glutamate α-amino-propionic- acid (AMPA)/kainate receptors by antidepressant drugs. / Barbon, Alessandro; Popoli, Maurizio; La Via, Luca; Moraschi, Stefania; Vallini, Ivan; Tardito, Daniela; Tiraboschi, Ettore; Musazzi, Laura; Giambelli, Roberto; Gennarelli, Massimo; Racagni, Giorgio; Barlati, Sergio.

In: Biological Psychiatry, Vol. 59, No. 8, 15.04.2006, p. 713-720.

Research output: Contribution to journalArticle

Barbon, A, Popoli, M, La Via, L, Moraschi, S, Vallini, I, Tardito, D, Tiraboschi, E, Musazzi, L, Giambelli, R, Gennarelli, M, Racagni, G & Barlati, S 2006, 'Regulation of editing and expression of glutamate α-amino-propionic- acid (AMPA)/kainate receptors by antidepressant drugs', Biological Psychiatry, vol. 59, no. 8, pp. 713-720. https://doi.org/10.1016/j.biopsych.2005.10.018
Barbon, Alessandro ; Popoli, Maurizio ; La Via, Luca ; Moraschi, Stefania ; Vallini, Ivan ; Tardito, Daniela ; Tiraboschi, Ettore ; Musazzi, Laura ; Giambelli, Roberto ; Gennarelli, Massimo ; Racagni, Giorgio ; Barlati, Sergio. / Regulation of editing and expression of glutamate α-amino-propionic- acid (AMPA)/kainate receptors by antidepressant drugs. In: Biological Psychiatry. 2006 ; Vol. 59, No. 8. pp. 713-720.
@article{ccd09a7a94344cb0933ddffc5a27348c,
title = "Regulation of editing and expression of glutamate α-amino-propionic- acid (AMPA)/kainate receptors by antidepressant drugs",
abstract = "Background: Several reports have shown that the glutamatergic system is involved in both the pathogenesis of affective and stress-related disorders and in the action of antidepressant drugs. In particular, antidepressant treatment was shown to modulate expression and function of ionotropic glutamate receptors, to inhibit glutamate release and to restore synaptic plasticity impaired by stress. Methods: We analyzed the mRNA expression and RNA editing of α-amino-propionic-acid (AMPA) and kainate (KA) receptor subunits, in the pre-frontal/frontal cortex (P/FC) and hippocampus (HI) of rats chronically treated with three different drugs: the selective serotonin (5-HT) reuptake inhibitor fluoxetine, the selective noradrenaline (NA) reuptake inhibitor reboxetine and the tricyclic antidepressant desipramine. Results: Our data showed that fluoxetine and desipramine exerted moderate but selective effects on glutamate receptor expression and editing, while reboxetine appeared to be the drug that affects glutamate receptors (GluR) most. The most consistent effect, observed with pronoradrenergic drugs (desipramine and reboxetine), was a decrease of GluR3 expression both in P/FC and HI. Interestingly, in HI, the same drugs also decreased the editing levels of either the flip (desipramine) or flop (reboxetine) form of GluR3. Conclusions: Overall, these results point to specific and regionally discrete changes in the expression and editing level of glutamate receptors and, in particular, to a selective reduction of conductance for GluR3-containing receptors following treatment with antidepressant drugs. These data support the hypothesis that changes in glutamate neurotransmission are involved in the therapeutic effects induced by these drugs.",
keywords = "Antidepressant, Expression, Glutamate receptors, RNA editing",
author = "Alessandro Barbon and Maurizio Popoli and {La Via}, Luca and Stefania Moraschi and Ivan Vallini and Daniela Tardito and Ettore Tiraboschi and Laura Musazzi and Roberto Giambelli and Massimo Gennarelli and Giorgio Racagni and Sergio Barlati",
year = "2006",
month = "4",
day = "15",
doi = "10.1016/j.biopsych.2005.10.018",
language = "English",
volume = "59",
pages = "713--720",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - Regulation of editing and expression of glutamate α-amino-propionic- acid (AMPA)/kainate receptors by antidepressant drugs

AU - Barbon, Alessandro

AU - Popoli, Maurizio

AU - La Via, Luca

AU - Moraschi, Stefania

AU - Vallini, Ivan

AU - Tardito, Daniela

AU - Tiraboschi, Ettore

AU - Musazzi, Laura

AU - Giambelli, Roberto

AU - Gennarelli, Massimo

AU - Racagni, Giorgio

AU - Barlati, Sergio

PY - 2006/4/15

Y1 - 2006/4/15

N2 - Background: Several reports have shown that the glutamatergic system is involved in both the pathogenesis of affective and stress-related disorders and in the action of antidepressant drugs. In particular, antidepressant treatment was shown to modulate expression and function of ionotropic glutamate receptors, to inhibit glutamate release and to restore synaptic plasticity impaired by stress. Methods: We analyzed the mRNA expression and RNA editing of α-amino-propionic-acid (AMPA) and kainate (KA) receptor subunits, in the pre-frontal/frontal cortex (P/FC) and hippocampus (HI) of rats chronically treated with three different drugs: the selective serotonin (5-HT) reuptake inhibitor fluoxetine, the selective noradrenaline (NA) reuptake inhibitor reboxetine and the tricyclic antidepressant desipramine. Results: Our data showed that fluoxetine and desipramine exerted moderate but selective effects on glutamate receptor expression and editing, while reboxetine appeared to be the drug that affects glutamate receptors (GluR) most. The most consistent effect, observed with pronoradrenergic drugs (desipramine and reboxetine), was a decrease of GluR3 expression both in P/FC and HI. Interestingly, in HI, the same drugs also decreased the editing levels of either the flip (desipramine) or flop (reboxetine) form of GluR3. Conclusions: Overall, these results point to specific and regionally discrete changes in the expression and editing level of glutamate receptors and, in particular, to a selective reduction of conductance for GluR3-containing receptors following treatment with antidepressant drugs. These data support the hypothesis that changes in glutamate neurotransmission are involved in the therapeutic effects induced by these drugs.

AB - Background: Several reports have shown that the glutamatergic system is involved in both the pathogenesis of affective and stress-related disorders and in the action of antidepressant drugs. In particular, antidepressant treatment was shown to modulate expression and function of ionotropic glutamate receptors, to inhibit glutamate release and to restore synaptic plasticity impaired by stress. Methods: We analyzed the mRNA expression and RNA editing of α-amino-propionic-acid (AMPA) and kainate (KA) receptor subunits, in the pre-frontal/frontal cortex (P/FC) and hippocampus (HI) of rats chronically treated with three different drugs: the selective serotonin (5-HT) reuptake inhibitor fluoxetine, the selective noradrenaline (NA) reuptake inhibitor reboxetine and the tricyclic antidepressant desipramine. Results: Our data showed that fluoxetine and desipramine exerted moderate but selective effects on glutamate receptor expression and editing, while reboxetine appeared to be the drug that affects glutamate receptors (GluR) most. The most consistent effect, observed with pronoradrenergic drugs (desipramine and reboxetine), was a decrease of GluR3 expression both in P/FC and HI. Interestingly, in HI, the same drugs also decreased the editing levels of either the flip (desipramine) or flop (reboxetine) form of GluR3. Conclusions: Overall, these results point to specific and regionally discrete changes in the expression and editing level of glutamate receptors and, in particular, to a selective reduction of conductance for GluR3-containing receptors following treatment with antidepressant drugs. These data support the hypothesis that changes in glutamate neurotransmission are involved in the therapeutic effects induced by these drugs.

KW - Antidepressant

KW - Expression

KW - Glutamate receptors

KW - RNA editing

UR - http://www.scopus.com/inward/record.url?scp=33645346211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645346211&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2005.10.018

DO - 10.1016/j.biopsych.2005.10.018

M3 - Article

VL - 59

SP - 713

EP - 720

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 8

ER -